Generation of a gene-corrected isogenic control hiPSC line derived from a familial Alzheimer's disease patient carrying a L150P mutation in presenilin 1 Mutations in the presenilin 1 (PSEN1) gene lead to the most aggressive form of familial Alzheimer's disease (AD). Human induced pluripotent stem cells (hiPSCs) derived from AD patients and subsequently differentiated can be used for disease modeling. We have previously generated a hiPSC line from a familial AD patient carrying a L150P point mutation in PSEN1. Here we used CRISPR/Cas9 gene editing to correct for the single base pair mutation. This gene-corrected line, L150P-GC-hiPSC, serves as an isogenic control to the mutant line for future investigation of mechanisms and cellular phenotypes altered by this specific PSEN1 mutation. 
Resource details
A human induced pluripotent stem cell (hiPSC) line was previously generated from a skin biopsy obtained from a 58-year-old male Alzheimer's disease (AD) patient carrying a heterozygous point mutation (c.449C N T) in exon 6 of the presenilin 1 (PSEN1) gene (Tubsuwan et al., 2016) . The single base pair mutation results in the substitution of leucine (L) to proline (P) at position 150 of the amino acid sequence (i.e., L150P). To generate a patient-specific and integration-free hiPSC line, episomal plasmids carrying gene sequences for hOCT4, hSOX2, hKLF4, hL-MYC, hLIN28 and a short hairpin against TP53 (Okita et al., 2011) were used to reprogram patient's fibroblasts into hiPSCs (Tubsuwan et al., 2016) . Here, we used this hiPSC line to further generate an isogenic control line, L150P-GC-hiPSC, by employing the CRISPR/Cas9 system (Ran et al., 2013) to correct the c.449CN T mutation. Genomic sequences manipulated for gene editing are shown in Fig. 1A . Correction of the point mutation (C N T) was validated by sequencing (Fig. 1B) . The L150P-GC-hiPSC was characterized to be karyotype normal with 46, XY ( E-mail address: kkf@sund.ku.dk (K.K. Freude).
Resource 
Contents lists available at ScienceDirect
Stem Cell Research j o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / s c r OCT4, NANOG, SSEA3, SSEA4, TRA-1-60 and TRA-1-81 (Fig. 1D ). This study was approved by the "De Videnskabsetiske Komiteer for Region Hovedstaden" (protocol number H-4-2011-157), Copenhagen, Denmark, and informed consent was obtained from the patient and his family. As part of privacy protection, no personal information of the patient is provided here.
Materials and methods

CRISPR design
The isogenic gene-corrected control L150P-GC-hiPSC was generated using the CRISPR/Cas9 technology in combination with single-stranded oligonucleotides (ssODNs) to guide the site-specific correction of the L150P mutation.
We adopted the protocol published by Ran et al. (2013) and designed the single-guide RNAs (sgRNAs) using the Zhang Lab software (http://crispr.mit.edu/). The sgRNAs was cloned into Cas9 expressing plasmids (pSpCas9(BB)-2 A-Puro (PX459) V2.0; addgene ID 62988). The ssODN contained the T (i.e., wild-type) nucleotide to replace the mutant "C" at the site of mutation. It also contained two additional silent mutations, one up-and one down-stream of the mutation site for positive colony selection with the appropriate restriction enzyme.
Nucleofection L150P-hiPSCs grown on matrigel-coated (Corning Bioscience) dishes with E8 medium (Gibco) were detached with Accutase (Gibco). 2 × 10 6 single cells were transfected with 10 μg of CRISPR/Cas9 plasmid and 100 pmol of ssODN using the Amaxa 4D Nucleofector (program CA137, Lonza) and P3 Primary Cell Kit (Lonza) according to the manufacturer's instructions. Transfected hiPSCs were cultured on matrigel-coated dish with E8 medium supplemented with 1 mM ROCK inhibitor (Sigma). Transfected hiPSCs were then subjected to puromycin selection 4 h after nucleofection and cultured in the presence of puromycin for the next 5 days. Puromycin-resistant colonies were manually picked into 96 well plates coated with matrigel and expanded in the E8 medium.
Genotyping and restriction assays
DNA for genotyping was extracted using the prepGem™ Kit (ZyGEM, PTI0500) (Qiagen). PCR with primers spanning the site of mutation was performed using TEMPase Hot Start DNA Polymerase (Ampliqon) according to the manufacturer's instructions. PCR products were purified and digested with BseNI (Thermo Scientific) at 65°C for 20 min. This enzyme only cuts DNA from hiPSC colonies with the corrected allele from the ssODN containing the T nucleotide at the mutation site.
Sanger sequencing
Positive clones were sequenced using the ABI PRISM 310 Genetic Analyzer for the presence of the corrected nucleotide at the site of mutation. Sequences were also inspected for frameshifts and mutations that might arise from the CRISPR-mediated gene editing.
Immunofluorescence staining L150-GC-hiPSCs were fixed with 4% paraformaldehyde in PBS for 15 min, blocked, and incubated with primary antibodies listed in Table  1 overnight at 4°C. The next day, cells were incubated with the appropriate secondary antibodies and counterstained with DAPI. Images were acquired using the Leica DMRB-fluorescence microscope (Leica Microsystems, Wetzlar, Germany).
Karyotyping
L150-GC-hiPSCs were karyotyped using standard cytogenetic procedures. In brief, cells were treated for 45 min with KaryoMAX colcemid (Life Technologies), harvested in fresh fixative consisted of 25% acetic acid and 75% methanol, and subjected for G-band karyotyping at the Institute of Medical Genetics and Applied Genomics (University of Tübingen, Tübingen, Germany).
Verification and Authentication.
L150-GC-hiPSC karyotyping was performed by the Institute of Medical Genetics and Applied Genomics, University of Tübingen (Tübingen, Germany). A minimum of 20 metaphases were analyzed. The results showed a normal 46, XY karyotype without any detectable abnormalities (Fig. 1C) . The identity and purity of this line was confirmed by sequencing of PSEN1 (Fig. 1B) and expression of several pluripotency genes (Fig. 1D) . Fig. 1D . Immunofluorescence staining of L150P-GC-iPSCs with pluripotency markers: OCT4, NANOG, SSEA3, SSEA4, TRA1-60 and TRA1-81. Scale bars correspond to 100 μm.
